financetom
Business
financetom
/
Business
/
Looking at 25% growth after expansion: UFlex
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking at 25% growth after expansion: UFlex
Feb 12, 2021 4:05 AM

UFlex reported a good set of Q3 results with a strong performance in the flexible packaging and engineering segment. The company has announced a capacity expansion for its packaging films segment.

To discuss its earnings and the outlook for the rest of the year Rajesh Bhatia, Group President (Finance & Accounts) & CFO of the company spoke to CNBC-TV18. "This capex that we have announced it is only for the packaging films, we are getting into this investment after a gap of 16 years on the packaging films side so the current capacities utilisation has now been 100 and above for the last so many years.”

"However, we were doing expansion in our overseas business and we were consolidating our aseptic packaging investments so now is the right time and this FY21 we will see a huge increase in our EBITDA from the previous year’s levels. FY22 onwards next couple of years we are looking at about 25 percent kind of growth given that a whole lot of capacities have come on stream," he added.

On guidance for the aseptic packaging division, he said, "FY22 for the aseptic packaging forgetting the new line which is going to be ready by December of this year we will have close to about Rs 500 crore of the topline and we have healthy EBITDA margins over there in the north of 20 percent."

For the full management interview, watch the video.

(Edited by : Priyanka Rathi)

First Published:Feb 12, 2021 1:05 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA advisers to review Eli Lilly Alzheimer's drug
US FDA advisers to review Eli Lilly Alzheimer's drug
Jun 10, 2024
By Bhanvi Satija and Julie Steenhuysen June 10 (Reuters) - An independent advisory panel to the U.S. Food and Drug Administration will vote later on Monday on the safety and effectiveness of Eli Lilly's ( LLY ) experimental Alzheimer's drug donanemab. Donanemab, if approved, would compete with Eisai ( ESALF ) and Biogen's Leqembi. Both drugs are designed to remove...
Cuba woos Russians, Chinese to revive ailing tourist sector
Cuba woos Russians, Chinese to revive ailing tourist sector
Jun 10, 2024
HAVANA (Reuters) - Russian tourist Serguei Boyaryshnic wandered in awe among the pastel-colored buildings and cobblestone streets of Old Havana on a weekday morning, his family in tow. We had heard a lot about Cuba. Our countries have been friends for years, said the 36-year-old Moscow resident, who had joined a small tour group. We love everything about it. Cuba...
Market Chatter: Norway Wealth Fund Opposes Tesla CEO Musk's $56 Billion Pay
Market Chatter: Norway Wealth Fund Opposes Tesla CEO Musk's $56 Billion Pay
Jun 10, 2024
07:04 AM EDT, 06/10/2024 (MT Newswires) -- Norway's $1.7 trillion sovereign wealth fund will vote against ratifying Tesla chief (TSLA) Elon Musk's $56 billion pay package, which a Delaware judge invalidated earlier this year, Reuters reported on Saturday. We remain concerned about the total size of the award, the structure given performance triggers, dilution, and lack of mitigation of key...
AstraZeneca's Tagrisso Secures Priority Review in the US
AstraZeneca's Tagrisso Secures Priority Review in the US
Jun 10, 2024
07:09 AM EDT, 06/10/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its supplemental new drug application for Tagrisso has been accepted and granted priority review in the US for the treatment of adult patients with unresectable, stage III epidermal growth factor receptor-mutated non-small cell lung cancer after chemoradiotherapy. The Food and Drug Administration action date for a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved